Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new ...

BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine ...

The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric ...

After a tension-packed two days that saw changes to the MMRV vaccine schedule and COVID-19 recommendations, as well as a ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck ...

DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...

Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...

Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time ...